1. Home
  2. RYAN vs GRFS Comparison

RYAN vs GRFS Comparison

Compare RYAN & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryan Specialty Holdings Inc.

RYAN

Ryan Specialty Holdings Inc.

N/A

Current Price

$37.25

Market Cap

6.1B

Sector

Finance

ML Signal

N/A

Logo Grifols S.A.

GRFS

Grifols S.A.

N/A

Current Price

$8.32

Market Cap

5.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RYAN
GRFS
Founded
2010
1940
Country
United States
Spain
Employees
N/A
25247
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1B
5.8B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
RYAN
GRFS
Price
$37.25
$8.32
Analyst Decision
Buy
Hold
Analyst Count
15
2
Target Price
$56.50
$10.15
AVG Volume (30 Days)
2.9M
632.9K
Earning Date
05-15-2026
01-01-0001
Dividend Yield
1.31%
1.66%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,051,126,000.00
N/A
Revenue This Year
$18.15
$5.33
Revenue Next Year
$13.74
$6.50
P/E Ratio
$86.72
$18.67
Revenue Growth
21.28
N/A
52 Week Low
$37.29
$6.19
52 Week High
$77.00
$11.14

Technical Indicators

Market Signals
Indicator
RYAN
GRFS
Relative Strength Index (RSI) 30.76 33.82
Support Level N/A $8.25
Resistance Level $59.01 $9.11
Average True Range (ATR) 1.55 0.30
MACD 0.20 -0.09
Stochastic Oscillator 10.61 1.21

Price Performance

Historical Comparison
RYAN
GRFS

About RYAN Ryan Specialty Holdings Inc.

Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: